CTOs on the Move

Y C C Products Inc

www.yccnails.com

 
Y C C Products Inc is a Placentia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.yccnails.com
  • 1740 Barcelona Cir
    Placentia, CA USA 92870
  • Phone: 714.985.8989

Executives

Name Title Contact Details

Similar Companies

Louisiana Organ Procurement Agency

Louisiana Organ Procurement Agency is a Metairie, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Surgery Partners

Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high-quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 180 locations in 31 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities.

Rotech Healthcare

Rotech Healthcare Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Rotech Healthcare Inc. is based in Orlando, FL. You can find more information on Rotech Healthcare Inc. at www.rotech.com

Thibodaux Regional Medical Center

Thibodaux Regional Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Thibodaux Regional Medical Center is based in Thibodaux, LA. You can find more information on Thibodaux Regional Medical Center at www.thibodaux.com

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.